Top

Published in:

01-02-2017 | Case Report

Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

Authors: Alberto Hernández-Tejedor, Carmen Débora Merino-Vega, Alfredo Martín-Vivas, Rafael Ruiz de Luna-González, Alberto Delgado-Iribarren, Ángeles Gabán-Díez, Ignacio Temprano-Gómez, Natalia de la Calle-Pedrosa, Ana Isabel González-Jiménez, Alejandro Algora-Weber

Published in: Infection | Issue 1/2017

Abstract

Introduction

Ceftolozane/tazobactam is a novel antibiotic approved for the treatment of complicated intra-abdominal and complicated urinary tract infections.

Case description

We describe the use of off-label ceftolozane/tazobactam in the management of a multidrug-resistant Pseudomonas aeruginosa bacteremia that was already being treated with colistin and amikacin, the only active antibiotics according to the antibiogram.

Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-008) (ASPECT-NP). https://clinicaltrials.gov/ct2/show/NCT02070757. Accessed 30 May 2016.

Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–5.CrossRefPubMed

Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.CrossRefPubMed

Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy. 2016;36:e30–3.CrossRefPubMed

Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane–tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218–23.CrossRefPubMedPubMedCentral

Title: Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam
Authors: Alberto Hernández-Tejedor
Carmen Débora Merino-Vega
Alfredo Martín-Vivas
Rafael Ruiz de Luna-González
Alberto Delgado-Iribarren
Ángeles Gabán-Díez
Ignacio Temprano-Gómez
Natalia de la Calle-Pedrosa
Ana Isabel González-Jiménez
Alejandro Algora-Weber
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 1/2017
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0944-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

Abstract

Introduction

Case description

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Case description

Please log in to get access to this content

Other articles of this Issue 1/2017

Time trends in Staphylococcus aureus bacteremia, 1988–2010, in a tertiary center with high methicillin resistance rates

Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study

Complement 5a is an indicator of significant fibrosis and earlier cirrhosis in patients chronically infected with hepatitis B virus

The lord of the broken rings: African porocephaliasis, an emerging radiological diagnosis in developed countries

Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern

“Nudging” in microbiological reports: a strategy to improve prescribing

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page